Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.27 is in line with its 5-year average of -0.25, near the low end of its 5-year range (-1.60–8.68).
As of the fiscal period ended Tuesday, June 30, 2026. 66.73% above its 12-month average of -0.80.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.27.
DEBT TO EQUITY RATIO
-0.27
DEBT TO EQUITY RATIO AVG TTM
-0.80
DEBT TO EQUITY RATIO AVG 3Y
-0.49
DEBT TO EQUITY RATIO AVG 5Y
-0.25
DEBT TO EQUITY RATIO AVG 10Y
-0.09
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+66.73%
CURRENT VS 3Y AVG
+45.52%
CURRENT VS 5Y AVG
-7.56%
CURRENT VS 10Y AVG
-205.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.17
median of 346 covered companies
CURRENT VS SECTOR MEDIAN
-257.08%
vs the sector median at left
Atara Biotherapeutics, Inc.
Market Cap
$84.70M
Debt to Equity Ratio
-0.27
TTM Avg
-0.80
3Y Avg
-0.49
5Y Avg
-0.25
Market Cap
$84.75M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$83.96M
Debt to Equity Ratio
0.02
TTM Avg
0.03
3Y Avg
0.04
5Y Avg
0.03
Market Cap
$83.49M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$87.86M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.03
5Y Avg
0.02
Market Cap
$81.22M
Debt to Equity Ratio
0.25
TTM Avg
0.08
3Y Avg
0.04
5Y Avg
0.04
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | $84.70M | -0.27 | -0.80 | -0.49 | -0.25 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | 0.02 | 0.02 | 0.03 | 0.03 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | 0.02 | 0.03 | 0.04 | 0.03 |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 3.10 | 0.07 | 0.16 | 0.15 |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | 0.02 | 0.02 | 0.03 | 0.02 |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | 0.25 | 0.08 | 0.04 | 0.04 |
| electroCore, Inc. (ECOR)vs › | $91.33M | N/A | 0.32 | 0.17 | 0.15 |
| Equillium, Inc. (EQ)vs › | $91.68M | 0.01 | 0.03 | 0.10 | 0.12 |
| Biomea Fusion, Inc. (BMEA)vs › | $93.99M | 0.07 | 0.11 | 0.07 | 0.06 |
Debt/Equity
-0.27
Current Ratio
1.98
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.27 |
| 2026-03-31 | -0.27 |
| 2025-12-31 | -1.37 |
| 2025-09-30 | -1.60 |
| 2025-06-30 | -0.50 |
| 2025-03-31 | -0.74 |
| 2024-12-31 | -0.45 |
| 2024-09-30 | -0.55 |
| 2024-06-30 | -0.48 |
| 2024-03-31 | -0.57 |
| 2023-12-31 | -0.58 |
| 2023-09-30 | -1.22 |
| 2023-06-30 | 8.68 |
| 2023-03-31 | 0.85 |
| 2022-12-31 | 0.57 |
| 2022-09-30 | 0.33 |
| 2022-06-30 | 0.25 |
| 2022-03-31 | 0.08 |
| 2021-12-31 | 0.10 |
| 2021-09-30 | 0.08 |
| 2021-06-30 | 0.04 |
| 2021-03-31 | 0.03 |
| 2020-12-31 | 0.03 |
| 2020-09-30 | 0.04 |
| 2020-06-30 | 0.04 |
| 2020-03-31 | 0.05 |
| 2019-12-31 | 0.05 |
| 2019-09-30 | 0.05 |
| 2019-06-30 | 0.06 |
| 2019-03-31 | 0.05 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.03 |
| 2018-06-30 | 0.02 |
| 2018-03-31 | 0.02 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | 0.00 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
| 2013-12-31 | 0.00 |
| 2013-09-30 | 0.00 |
| 2013-06-30 | 0.00 |
| 2013-03-31 | 0.00 |
